Intelligent Bio Solutions Inc.(INBS)Earnings, Financials & Key Ratios
INBS•NASDAQ
$2.41
$3M mkt cap·Price updated May 6, 2026
AboutIntelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Show more
- Revenue$3M-1.9%
- EBITDA-$10M-3.9%
- Net Income-$11M-4.1%
- EPS (Diluted)-20.00+68.7%
- Gross Margin40.85%-10.8%
- EBITDA Margin-316.93%-5.9%
- Operating Margin-348.71%-5.5%
- Net Margin-346.23%-6.1%
- ROE-192.21%-12.3%
- ROIC-313.01%-43.9%
- Debt/Equity0.10-28.5%
- Interest Coverage-174.82-184.1%
INBS Key Insights
Intelligent Bio Solutions Inc. (INBS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 74.5%
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 65.6% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
INBS Price & Volume
Intelligent Bio Solutions Inc. (INBS) stock price & volume — 10-year historical chart
Loading chart...
INBS Growth Metrics
Intelligent Bio Solutions Inc. (INBS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years74.48%
3 Years-
TTM18.14%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM65.48%
Return on Capital
10 Years-287.15%
5 Years-141.59%
3 Years-185.82%
Last Year-189.63%
INBS Peer Comparison
Intelligent Bio Solutions Inc. (INBS) competitors in Point-of-Care and Rapid Testing — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OPRX | 120.61M | 6.47 | 23.96 | 18.78% | 4.69% | 4.22% | 0.04 | |
 QDEL | 746.18M | 10.96 | -0.66 | -1.89% | -45.57% | -56.31% | 1.46 | |
 CUE | 89.3M | 33.98 | -4.05 | 195.75% | -96.85% | -165.19% | 0.16 | |
 SEER | 105.44M | 1.89 | -1.36 | -8.13% | -486.02% | -29.19% | 0.08 | |
 IDXX | 46.12B | 579.23 | 44.28 | 10.42% | 24.63% | 70.87% | 0.67 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 10.37% | 0.52 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 |
Compare INBS vs Peers
Intelligent Bio Solutions Inc. (INBS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INBS Income Statement
Intelligent Bio Solutions Inc. (INBS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 188.74K | 1.98M | 0 | 1.26M | 3.11M | 3.05M | 3.58M |
| Revenue Growth % | - | - | - | - | 949.3% | -100% | - | 147.58% | -1.9% | 18.14% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 930.2K | 1.69M | 1.81M | 1.93M |
| COGS % of Revenue | - | - | - | - | - | - | 74.01% | 54.19% | 59.15% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 188.74K▲ 0% | 1.98M▲ 949.3% | 0▼ 100.0% | 326.67K▲ 0% | 1.43M▲ 336.4% | 1.25M▼ 12.5% | 1.65M▲ 0% |
| Gross Margin % | - | - | - | 100% | 100% | - | 25.99% | 45.81% | 40.85% | 46.21% |
| Gross Profit Growth % | - | - | - | - | 949.3% | -100% | - | 336.41% | -12.54% | - |
| Operating Expenses | 173K | 4.6M | 6.73M | 3.05M | 7.55M | 8.34M | 12.92M | 11.71M | 11.89M | 12.19M |
| OpEx % of Revenue | - | - | - | 1613.69% | 381.42% | - | 1028.1% | 376.27% | 389.56% | - |
| Selling, General & Admin | 173K | 2.08M | 3.55M | 2.2M | 3.36M | 4.92M | 8.03M | 9.26M | 8.88M | 10.12M |
| SG&A % of Revenue | - | - | - | 1167.26% | 169.61% | - | 638.63% | 297.53% | 291.03% | - |
| Research & Development | 0 | 2.53M | 3.18M | 588.21K | 3.84M | 3.85M | 507.42K | 1.67M | 2.4M | 1.81M |
| R&D % of Revenue | - | - | - | 311.64% | 193.68% | - | 40.37% | 53.79% | 78.51% | - |
| Other Operating Expenses | 0 | 0 | 0 | 254.41K | 359.2K | -437.15K | 4.39M | 776.5K | 611.04K | 250.35K |
| Operating Income | -173K▲ 0% | -4.6M▼ 2560.7% | -5.83M▼ 26.7% | -2.86M▲ 51.0% | -5.57M▼ 95.1% | -8.34M▼ 49.6% | -12.6M▼ 51.1% | -10.28M▲ 18.4% | -10.64M▼ 3.5% | -11.29M▲ 0% |
| Operating Margin % | - | - | - | -1513.69% | -281.42% | - | -1002.11% | -330.46% | -348.71% | -315.28% |
| Operating Income Growth % | - | -2560.69% | -26.74% | 51.03% | -95.08% | -49.58% | -51.08% | 18.36% | -3.51% | - |
| EBITDA | 15.72K | 0 | 0 | -254.41K | -359.2K | -8.33M | -11.63M | -9.31M | -9.67M | -10.67M |
| EBITDA Margin % | - | - | - | -134.79% | -18.14% | - | -925.19% | -299.15% | -316.93% | -297.86% |
| EBITDA Growth % | - | -100% | - | - | -41.19% | -2218.06% | -39.66% | 19.95% | -3.93% | -11.94% |
| D&A (Non-Cash Add-back) | 188.72K | 4.6M | 5.83M | 2.6M | 5.21M | 0 | 966.73K | 974.36K | 970.12K | 623.76K |
| EBIT | -173K | -4.6M | -6.73M | -2.6M | -5.21M | -8.33M | -10.44M | -10.28M | -10.42M | -8.61M |
| Net Interest Income | 0 | -453K | -665K | -458K | -1.08M | 6.89K | -214K | -82.32K | 40.63K | 6.29K |
| Interest Income | 151.28K | 0 | 188 | 97 | 13.81K | 14.43K | 9.68K | 84.82K | 101.52K | 40.58K |
| Interest Expense | 0 | 453.87K | 664.84K | 457.75K | 1.09M | 7.54K | 223.53K | 167.14K | 60.89K | -27.25K |
| Other Income/Expense | -139K | -453K | -1.56M | -335.96K | -1.49M | 2.9K | 1.93M | 92.24K | 39.72K | -21.8K |
| Pretax Income | -312K▲ 0% | -5.06M▼ 1520.8% | -7.39M▼ 46.2% | -3.19M▲ 56.8% | -7.06M▼ 121.1% | -8.33M▼ 18.0% | -10.66M▼ 28.0% | -10.19M▲ 4.4% | -10.6M▼ 4.1% | -11.3M▲ 0% |
| Pretax Margin % | - | - | - | -1691.68% | -356.49% | - | -848.5% | -327.5% | -347.41% | -315.55% |
| Income Tax | 0 | -36.39K | -57.69K | 0 | 0 | 0 | 0 | 0 | 0 | 12.88K |
| Effective Tax Rate % | 0% | 0.72% | 0.78% | 0% | 0% | 0% | 0% | 0% | 0% | -0.11% |
| Net Income | -340K▲ 0% | -5.02M▼ 1376.5% | -7.34M▼ 46.2% | -3.16M▲ 56.9% | -7.04M▼ 122.4% | -8.31M▼ 18.0% | -10.63M▼ 28.0% | -10.16M▲ 4.5% | -10.57M▼ 4.1% | -11.29M▲ 0% |
| Net Margin % | - | - | - | -1676.23% | -355.33% | - | -845.89% | -326.4% | -346.23% | -315.35% |
| Net Income Growth % | - | -1376.47% | -46.16% | 56.88% | -122.43% | -18.03% | -28% | 4.47% | -4.06% | -5.58% |
| Net Income (Continuing) | -312K | -5.06M | -7.39M | -3.19M | -7.06M | -8.33M | -10.66M | -10.19M | -10.6M | -8.64M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 1.31M | 637.92K | -28.31K | -51.23K | -79.15K | -111.99K | -146.16K | -182.31K | -203.32K |
| EPS (Diluted) | -9.90▲ 0% | -146.00▼ 1374.7% | -210.10▼ 43.9% | -89.20▲ 57.5% | -162.20▼ 81.8% | -113.30▲ 30.1% | -105.80▲ 6.6% | -63.80▲ 39.7% | -20.00▲ 68.7% | -11.88▲ 0% |
| EPS Growth % | - | -1374.75% | -43.9% | 57.54% | -81.84% | 30.15% | 6.62% | 39.7% | 68.65% | 65.48% |
| EPS (Basic) | -9.90 | -146.00 | -210.10 | -89.20 | -162.20 | -113.30 | -105.80 | -63.80 | -20.00 | - |
| Diluted Shares Outstanding | 60.4K | 60.4K | 60.4K | 70.92K | 52.07K | 73.33K | 200.9K | 318.5K | 527.36K | 950.83K |
| Basic Shares Outstanding | 60.4K | 60.4K | 60.4K | 70.92K | 52.07K | 73.33K | 200.9K | 318.5K | 527.36K | 950.83K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INBS Balance Sheet
Intelligent Bio Solutions Inc. (INBS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 667.23K | 2.5M | 2.33M | 476.33K | 18.21M | 10.87M | 3.86M | 8.53M | 4.14M | 12.17M |
| Cash & Short-Term Investments | 56.03K | 418.42K | 197.94K | 427.27K | 12.57M | 8.28M | 1.54M | 6.3M | 1.02M | 740.37K |
| Cash Only | 56.03K | 418.42K | 197.94K | 427.27K | 12.57M | 8.24M | 1.54M | 6.3M | 1.02M | 740.37K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 46.6K | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 36.48K | 94.5K | 19.59K | 2.1M | 1.53M | 833.16K | 978.35K | 1.6M | 456.66K |
| Days Sales Outstanding | - | - | - | 37.89 | 386.82 | - | 241.95 | 114.76 | 191.21 | 96.95 |
| Inventory | 0 | 2.03M | 1.98M | 0 | 0 | 0 | 979.91K | 777.54K | 635.22K | 590.25K |
| Days Inventory Outstanding | - | - | - | - | - | - | 384.5 | 168.31 | 128.4 | 120.18 |
| Other Current Assets | 611.19K | 2M | 0 | 0 | 3.21M | 936.68K | 34.1K | 111.19K | 394.66K | 10.39M |
| Total Non-Current Assets | 611.19K | 1.98M | 1.98M | 2M | 3.65M | 1.48M | 6.49M | 5.24M | 4.11M | 5.48M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 391.41K | 1.24M | 872.59K | 320.85K | 2.21M |
| Fixed Asset Turnover | - | - | - | - | - | - | 1.02x | 3.57x | 9.51x | 2.71x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 5.26M | 4.37M | 3.79M | 3.27M |
| Long-Term Investments | 0 | 0 | 0 | 135.69K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 611.19K | 1.98M | 1.98M | 1.86M | 3.65M | 1.09M | 0 | 0 | 0 | 0 |
| Total Assets | 667.23K▲ 0% | 2.5M▲ 274.1% | 2.33M▼ 6.7% | 2.48M▲ 6.3% | 21.86M▲ 783.0% | 12.35M▼ 43.5% | 10.35M▼ 16.2% | 13.78M▲ 33.1% | 8.25M▼ 40.1% | 17.65M▲ 0% |
| Asset Turnover | - | - | - | 0.08x | 0.09x | - | 0.12x | 0.23x | 0.37x | 0.31x |
| Asset Growth % | - | 274.07% | -6.73% | 6.34% | 782.98% | -43.49% | -16.17% | 33.07% | -40.13% | -7.74% |
| Total Current Liabilities | 6.58M | 5.56M | 6.31M | 7.69M | 3.68M | 4.66M | 5.88M | 5.45M | 5.35M | 5.13M |
| Accounts Payable | 339.17K | 167.47K | 849.72K | 483.58K | 1.36M | 715.9K | 1.2M | 602.34K | 897.26K | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | 469.38 | 130.39 | 181.37 | 294.65 |
| Short-Term Debt | 3.53M | 4.84M | 5.13M | 5.13M | 0 | 0 | 576.66K | 790.12K | 197.15K | 395.52K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 2.34M | 2.49M | 2.17M | 4.45M |
| Other Current Liabilities | 2.71M | 466.27K | 50.41K | 1.83M | 2.1M | 2.84M | 1.19M | 332.34K | 534.99K | 4.73M |
| Current Ratio | 0.10x | 0.45x | 0.37x | 0.06x | 4.94x | 2.33x | 0.66x | 1.57x | 0.77x | 0.77x |
| Quick Ratio | 0.10x | 0.08x | 0.05x | 0.06x | 4.94x | 2.33x | 0.49x | 1.42x | 0.65x | 0.65x |
| Cash Conversion Cycle | - | - | - | - | - | - | 157.07 | 152.68 | 138.24 | -77.52 |
| Total Non-Current Liabilities | 3.87M | 5.01M | 0 | 0 | 3.17M | 1.14M | 783.93K | 144.94K | 84.92K | 1.64M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 759.03K | 0 | 0 | 1.53M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 356.17K | 81.32K | 0 | 1.45M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 3.17M | 1.14M | -331.26K | 63.62K | 84.92K | 364.56K |
| Total Liabilities | 6.58M | 5.56M | 6.31M | 7.69M | 6.85M | 5.81M | 6.67M | 5.6M | 5.44M | 6.76M |
| Total Debt | 3.53M | 4.84M | 5.13M | 5.13M | 0 | 0 | 1.92M | 1.15M | 281.81K | 1.92M |
| Net Debt | 3.48M | 4.42M | 4.93M | 4.71M | -12.57M | -8.24M | 378.05K | -5.16M | -738.1K | 1.18M |
| Debt / Equity | - | - | - | - | - | - | 0.52x | 0.14x | 0.10x | 0.10x |
| Debt / EBITDA | 224.77x | - | - | - | - | - | - | - | - | -0.18x |
| Net Debt / EBITDA | 221.21x | - | - | - | - | - | - | - | - | -0.11x |
| Interest Coverage | - | -10.14x | -8.78x | -6.24x | -5.09x | -1105.83x | -56.35x | -61.52x | -174.82x | 315.92x |
| Total Equity | -5.91M▲ 0% | -3.06M▲ 48.2% | -3.98M▼ 29.8% | -5.21M▼ 31.1% | 15.01M▲ 387.8% | 6.55M▼ 56.4% | 3.69M▼ 43.7% | 8.18M▲ 121.9% | 2.81M▼ 65.6% | 10.89M▲ 0% |
| Equity Growth % | - | 48.18% | -29.82% | -31.12% | 387.77% | -56.38% | -43.67% | 121.95% | -65.61% | -19.71% |
| Book Value per Share | -97.90 | -50.73 | -65.85 | -73.53 | 288.18 | 89.27 | 18.35 | 25.69 | 5.34 | 11.45 |
| Total Shareholders' Equity | -5.91M | -4.38M | -4.62M | -5.19M | 15.06M | 6.62M | 3.8M | 8.33M | 3M | 11.09M |
| Common Stock | 0 | 0 | 1.95M | 86.3K | 135.82K | 7.45K | 23.3K | 34.56K | 73.23K | 12.38K |
| Retained Earnings | -311.67K | -5.33M | -12.67M | -15.83M | -22.87M | -31.18M | -41.81M | -51.96M | -62.53M | -68.19M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -14 | -1 | -1 | 0 |
| Accumulated OCI | 2.72K | 571.11K | -216.87K | -363.95K | -661.26K | -788.13K | -575.5K | -712.61K | -327.94K | -266.08K |
| Minority Interest | 0 | 1.31M | 637.92K | -28.31K | -51.23K | -79.15K | -111.99K | -146.16K | -182.31K | -203.32K |
INBS Cash Flow Statement
Intelligent Bio Solutions Inc. (INBS) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -243.89K | -5.38M | -5.58M | -498.62K | -11.3M | -3.36M | -7.38M | -9.57M | -9.68M | -9.68M |
| Operating CF Margin % | - | - | - | -264.18% | -570.39% | - | -586.96% | -307.59% | -317.03% | - |
| Operating CF Growth % | - | -2107.84% | -3.58% | 91.06% | -2165.56% | 70.27% | -119.69% | -29.74% | -1.1% | 25.63% |
| Net Income | -311.67K | -5.06M | -7.39M | -3.19M | -7.06M | -8.33M | -10.66M | -10.19M | -10.6M | -11.29M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 966.73K | 1.21M | 1.21M | 1.19M |
| Stock-Based Compensation | 0 | 0 | 1.95M | 0 | 0 | 0 | 260K | 230.5K | 238.04K | 97.58K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -62.35K | -36.39K | 1.89M | 67.26K | 704.36K | 2.54M | 1.98M | -122.29K | 196.56K | 872.9K |
| Working Capital Changes | 65.07K | -327.88K | -132.81K | 2.63M | -4.94M | 2.44M | 78.92K | -701.93K | -720.78K | -203.54K |
| Change in Receivables | 0 | 0 | 0 | 118.06K | -1.03M | 2.5M | 591.79K | -13.81K | -2.86M | -3.04M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -345.39K | 202.37K | 142.32K | 111.03K |
| Change in Payables | 65.07K | -327.88K | -132.81K | 2.41M | -973K | 242.66K | 84.5K | -632.95K | 0 | -521.66K |
| Cash from Investing | 0 | 0 | 0 | -14K | 0 | -880.22K | -694.14K | -221.43K | -231.84K | -321.38K |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | -380.22K | -505.12K | -221.43K | -231.84K | -361.54K |
| CapEx % of Revenue | - | - | - | - | - | - | 40.19% | 7.12% | 7.59% | - |
| Acquisitions | 0 | 0 | 0 | -14K | 0 | 0 | -189.02K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40.16K |
| Cash from Financing | 299.92K | 5.18M | 5.32M | 733.86K | 23.4M | 0 | 1.44M | 14.56M | 4.6M | 8.16M |
| Debt Issued (Net) | 3.85M | 1.43M | 0 | -150.99K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -168.71K | 0 | 0 | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 2.6M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -3.38M | 3.75M | 5.32M | -116.4K | -1.49M | 0 | -1.34M | 1.66M | 7.94K | 695.28K |
| Net Change in Cash | 59K▲ 0% | 362.39K▲ 514.2% | -220.48K▼ 160.8% | 229.33K▲ 204.0% | 12.15M▲ 5196.4% | -4.34M▼ 135.7% | -6.7M▼ 54.6% | 4.77M▲ 171.1% | -5.28M▼ 210.9% | -1.5M▲ 0% |
| Free Cash Flow | -243.89K▲ 0% | -5.38M▼ 2107.8% | -5.58M▼ 3.6% | -498.62K▲ 91.1% | -11.3M▼ 2165.6% | -3.74M▲ 66.9% | -7.88M▼ 110.9% | -9.79M▼ 24.2% | -9.91M▼ 1.2% | -9.74M▲ 0% |
| FCF Margin % | - | - | - | -264.18% | -570.39% | - | -627.15% | -314.71% | -324.62% | -272% |
| FCF Growth % | - | -2107.84% | -3.58% | 91.06% | -2165.56% | 66.91% | -110.86% | -24.24% | -1.19% | 5.21% |
| FCF per Share | -4.04 | -89.16 | -92.34 | -7.03 | -216.93 | -50.98 | -39.24 | -30.75 | -18.79 | -18.79 |
| FCF Conversion (FCF/Net Income) | 0.72x | 1.07x | 0.76x | 0.16x | 1.61x | 0.40x | 0.69x | 0.94x | 0.92x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 327.31K | 185.3K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INBS Key Ratios
Intelligent Bio Solutions Inc. (INBS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -143.74% | -77.08% | -207.8% | -171.13% | -192.21% | -103.71% |
| Return on Invested Capital (ROIC) | -254.25% | -378.16% | -956.85% | -434.4% | -1688.98% | -796.32% | -217.54% | -313.01% | -313.01% |
| Gross Margin | - | - | 100% | 100% | - | 25.99% | 45.81% | 40.85% | 46.21% |
| Net Margin | - | - | -1676.23% | -355.33% | - | -845.89% | -326.4% | -346.23% | -315.35% |
| Debt / Equity | - | - | - | - | - | 0.52x | 0.14x | 0.10x | 0.10x |
| Interest Coverage | -10.14x | -8.78x | -6.24x | -5.09x | -1105.83x | -56.35x | -61.52x | -174.82x | 315.92x |
| FCF Conversion | 1.07x | 0.76x | 0.16x | 1.61x | 0.40x | 0.69x | 0.94x | 0.92x | 0.86x |
| Revenue Growth | - | - | - | 949.3% | -100% | - | 147.58% | -1.9% | 18.14% |
INBS Frequently Asked Questions
Intelligent Bio Solutions Inc. (INBS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Intelligent Bio Solutions Inc. (INBS) reported $3.6M in revenue for fiscal year 2025.
Intelligent Bio Solutions Inc. (INBS) saw revenue decline by 1.9% over the past year.
Intelligent Bio Solutions Inc. (INBS) reported a net loss of $11.3M for fiscal year 2025.
Dividend & Returns
Intelligent Bio Solutions Inc. (INBS) has a return on equity (ROE) of -192.2%. Negative ROE indicates the company is unprofitable.
Intelligent Bio Solutions Inc. (INBS) had negative free cash flow of $9.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More INBS
Intelligent Bio Solutions Inc. (INBS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates